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Althoughmuch is known about themolecular players
in insulin signaling, there is scant information about
transcriptional regulation of its key components.
We now find that NUCKS is a transcriptional regu-
lator of the insulin signaling components, including
the insulin receptor (IR). Knockdown of NUCKS leads
to impaired insulin signaling in endocrine cells.
NUCKS knockout mice exhibit decreased insulin
signaling and increased body weight/fat mass along
with impaired glucose tolerance and reduced insulin
sensitivity, all of which are further exacerbated by a
high-fat diet (HFD). Genome-wide ChIP-seq iden-
tifies metabolism and insulin signaling as NUCKS
targets. Importantly, NUCKS is downregulated in
individuals with a high body mass index and in
HFD-fed mice, and conversely, its levels increase
upon starvation. Altogether, NUCKS is a physiolog-
ical regulator of energy homeostasis and glucose
metabolism that works by regulating chromatin
accessibility and RNA polymerase II recruitment to
the promoters of IR and other insulin pathway
modulators.
INTRODUCTION
Type 2 diabetes (T2D) and one of its major risk factors, obesity,
are pandemic problems (Friedman, 2009). Inherent genetic pre-
dispositions in combination with an inappropriate diet and a
sedentary lifestyle contribute to the pathogenesis of these
disorders (Ramachandrappa and Farooqi, 2011). T2D is charac-
terized by high blood glucose levels due to relative insulin defi-
ciency, the result of reduced insulin secretion and/or impaired
insulin sensitivity (Gustavsson et al., 2008). Defective response1876 Cell Reports 7, 1876–1886, June 26, 2014 ª2014 The Authorsto insulin often leads to serious metabolic disorders, including
hyperglycemia, dyslipidemia, and hypertension (Leavens and
Birnbaum, 2011). A better understanding of insulin signaling is
critical for the development of therapeutic strategies toward
T2D and obesity. Insulin activates a diverse array of biological re-
sponses by binding to its receptor (IR), which then phosphory-
lates and recruits different adaptors such as the insulin receptor
substrate (IRS) (Vollenweider et al., 2002). Phosphorylated IRS
proteins coordinate the activation of numerous well-defined
downstream signaling pathways, including the phosphatidylino-
sitol 3-kinase (PI3K) cascade (Bozulic and Hemmings, 2009).
PI3K signaling culminates in the activation of a multitude of
kinases including Akt/PKB and PKCz, which elicit the biological
action of insulin such as glycogen synthesis through GSK-3 or
protein synthesis via mTOR (Manning and Cantley, 2007). Insulin
signaling can be regulated at multiple levels (Taniguchi et al.,
2006), with transcriptional control, microRNA-mediated post-
transcriptional control (Trajkovski et al., 2011), posttranslational
modifications (Zick, 2005), changes in subcellular localization
(Inoue et al., 1998), protein degradation (Rui et al., 2002), and
modification of phosphoinositol phospholipid all known to play
a part (Sleeman et al., 2005). While many studies focus on nega-
tive regulators associated with impaired insulin signaling, the
positivemechanisms and their dysregulation during insulin resis-
tance are less explored.
As part of a directed screen to identify molecules that respond
to dietary cues in adipose tissue during development of
obesity and insulin resistance, we report the identification of
NUCKS (nuclear ubiquitous casein and cyclin-dependent kinase
substrate) as a regulator of insulin signaling. NUCKS was identi-
fied as a highly phosphorylated protein ubiquitously expressed in
vertebrates (Ostvold et al., 1990). NUCKS can be phosphory-
lated by casein kinase 2, cyclin-dependent kinases, DNA-acti-
vated protein kinase, and second messenger-activated kinases
(Meijer et al., 1991). Expression of NUCKS is deregulated in inva-
sive breast cancers (Drosos et al., 2009; Zio´1kowski et al., 2009).
These studies implicated NUCKS in signal transduction and
regulation of cell-cycle-related processes and DNA repair. How-
ever, the function of NUCKS beyond these signaling pathways
has not been reported. In this paper, we characterize the function
of NUCKS in the regulation of energy homeostasis and glucose
metabolism. Expression of NUCKS is inversely correlated with
body mass index (BMI) in humans and body fat in mice. Ablation
of NUCKS results in weight gain, increased body fat accumula-
tion, glucose intolerance, and insulin resistance. NUCKS plays
a critical role in insulin signaling and is required for efficient Akt
activation following insulin stimulation. Using chromatin immu-
noprecipitation sequencing (ChIP-seq), we show that NUCKS
is a key chromatin modifier and transcriptional regulator of a
number of insulin signaling genes, including IR.
RESULTS
Identification of NUCKS
To identify regulators of energy homeostasis and glucose meta-
bolism, we performed liquid chromatography-mass spectrom-
etry (LC-MS) analysis using white adipose tissue (WAT) lysates
from mice fed a low-fat diet (LFD) or a high-fat diet (HFD). We
performed reductive dimethyl (DM) labeling experiments (Fig-
ure 1A) of mixed peptides from LFD and HFD WAT samples, fol-
lowed by LC-MS analysis. In addition, the samples were also
subjected to label-free analysis. In this screen, we identified
more than 5,000 proteins, including several proteins detected
in LFD samples with significant iBAQ (intensity based absolute
quantification) value but absent in HFD samples (refer to Tables
S1 and S2 for complete proteomic analysis). Among these pro-
teins, we decided to focus on NUCKS, which was only detected
in LFD WAT samples (Figures 1B and 1C). NUCKS resembles
high-mobility group A (HMGA) proteins in amino acid composi-
tion and DNA binding domain structure. Despite being the
most modified protein in the genome (Wisniewski et al., 2008),
the physiological role of NUCKS is very poorly defined in the liter-
ature. The dramatic reduction of NUCKS in WAT from HFD-fed
mice prompted us to investigate if NUCKS may have important
functions in metabolic regulation.
Reduced NUCKS Levels in WAT of High-BMI Human
Subjects
Clinical relevance of NUCKS in obesity was evaluated by
measuring NUCKS expression levels in the subcutaneous fat
of human subjects with differing BMIs (Figure 1D). Overweight in-
dividuals (BMI > 25 kg/m2) displayed more than 40% reduction
in NUCKS protein levels when compared to lean individuals
(BMI < 23 kg/m2) (Figure 1E). Expression levels of NUCKS
showed a strong inverse correlation with BMI (Figure 1F). A sig-
nificant inverse correlation was also observed between NUCKS
expression and HOMA-IR (Figure 1G). Furthermore, like in hu-
mans, expression of NUCKS was drastically reduced in the
WAT of mice fed an HFD for 16 weeks when compared to age-
and sex-matched C57Bl6 mice on an LFD (Figures 1H and 1I).
Interestingly, IR levels were also lower in tissues from HFD-fed
mice (Figures 1H and 1I), suggesting a positive correlation
between NUCKS and IR expression. Besides WAT, NUCKS
was also markedly reduced in the liver, hypothalamus, and mus-
cle of HFD-fed mice (Figures S1A–S1F). On the other hand,CNUCKS protein and mRNA levels increased in starved MIHA
hepatocytes (Figures S1G and S1H) and several endocrine cells
(data not shown), indicating that NUCKSmay be amolecular link
between physiological cues and signaling that regulates energy
homeostasis.
NUCKS, present in the cytoplasm and nucleus (Grundt et al.,
2002, 2007), is composed of two nuclear localization signals
(NLS) and one DNA binding domain (DBD) (Figure S1I). We
examined whether NUCKS plays a direct role in insulin signaling.
First, we generated 3T3-L1 cells with stable knockdown (KD) of
NUCKS by using lentivirus-mediated small hairpin RNAs. Insulin-
stimulated Akt phosphorylation was reduced in NUCKS KD cells
(Figure S1J). To test the generality of our observations regarding
the role of NUCKS in insulin signaling and to evaluate whether
the KD effects were specific, we transfected another insulin-
responsive cell line, AML12 hepatocytes, with three independent
small interfering RNAs (siRNAs) against NUCKS and examined
insulin-induced Akt phosphorylation in these cells. Lowering
NUCKS expression by independent siRNAs resulted in reduced
Akt phosphorylation under all conditions (Figure S1K). Indeed,
NUCKS was required for insulin-mediated Akt phosphorylation
in a dose- (Figure S1L) and time-dependent (Figures S1M and
S1N) manner, suggesting that NUCKS is possibly an essential
positive regulator of insulin signaling. Taken together, these re-
sults indicate a strong inverse relationship between NUCKS
expression and obesity in mice and humans and suggest a
potential role of NUCKS in regulating insulin signaling.
Increased Body Weight and Reduced Energy
Expenditure in NUCKS Knockout Mice
To determine the physiological role of NUCKS in vivo, we gener-
ated NUCKS knockout (KO) mice (Figures S2A–S2D). NUCKS
KO animals were born at the expected Mendelian ratios and
were morphologically indistinguishable from their wild-type
(WT) littermates at birth (Figure S2E). NUCKS KO mice progres-
sively gained more weight when compared with WT mice over
the following 4 months when fed a normal chow diet (NCD) (Fig-
ure 2A). By 3 months of age, as compared to WT mice, NUCKS
KO mice show significantly higher body fat (Figure 2B). Weight
gain in NUCKS KO mice was mainly from liver and both visceral
and subcutaneous fat (Figure 2C). We then performed indirect
calorimetry analysis of paired NUCKS KO andWT mice. NUCKS
KO mice on the NCD consumed more food (Figure 2D) and ex-
hibited lower energy expenditure (Figure 2E) and lower basal
metabolic rates (Figure 2F) as compared to the age-matched
WT mice. The respiratory exchange rate was higher in the
NUCKS KO mice during the day (Figure 2G). Body temperature
was comparable between WT and KO mice fed a normal diet
(Figures S2F and S2G). NUCKS KO mice also displayed lower
locomotor activities at night and for the whole day as compared
to the age-matched WT mice (Figures 2H and 2I). The obese
phenotypes in NUCKS KO mice are exacerbated by an HFD.
NUCKS KO mice on an HFD gained significantly more body
weight (Figure 2J; Figure S2H) and body fat over time (Figure 2K).
The perirenal fat pads of the NUCKS KO mice were enlarged
(Figure S2I) with larger adipocytes compared to those of the
WT animals (Figure S2J). Hematoxylin and eosin staining and
oil red O staining showed more lipids in the cytosol of the KOell Reports 7, 1876–1886, June 26, 2014 ª2014 The Authors 1877
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Figure 1. Identification of NUCKS by Mass Spectrometry-Based Whole-Proteomics Analysis
(A) Workflow for mass spectrometry (MS) analysis of adipose tissues from mice on a low-fat diet (LFD) and high-fat diet (HFD). Two approaches (label-free and
reductive dimethyl labeling [DM]) were carried out to compare the protein expression levels between LFD and HFD samples.
(B) The table shows iBAQ (intensity-based absolute quantification) values in the label-free approach and peptide intensity in the DM approach. NUCKS was
detected in LFD, but not in HFD, samples for both approaches.
(C) MS spectrum of a detected NUCKS peptide further confirms its presence in an LFD sample, but not in an HFD sample. The asterisk (*) in red corresponding to
the heavy form of the NUCKS peptide was either below the noise level (very low expression) or not expressed at all.
(D) Immunoblot analysis of NUCKS expression in human subcutaneous fat. b-Actin was used as a loading control. The body mass index (BMI) of individuals is
shown on the top.
(E) Quantification of normalized NUCKS protein expression in human subcutaneous fat (n = 29).
(F) Correlation between normalized NUCKS expression and BMI in humans (n = 29).
(G) Correlation between normalized NUCKS expression and the HOMA-IR index in humans.
(H) Immunoblot analysis of NUCKS and IR expression in WAT 6-month-old mice fed a low- or high-fat diet (LFD or HFD, respectively) (n = 4).
(I) Real-time analysis of NUCKS and IR mRNA expression in WAT 6-month-old mice fed with a low- or high-fat diet (LFD or HFD, respectively) (n = 4).
*p < 0.05, **p < 0.01. See also Figure S1.
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Figure 2. Increased Body Weight and Fat Mass in NUCKS KO Mice Fed an NCD and HFD
(A) Body weight of WT and KO mice was monitored from 8 to 24 weeks of age (n = 9). Data are representative of three independent cohorts of mice.
(B) MRI of 3-month-old WT and KO mice. The fat and lean mass were expressed as absolute weight (n = 22).
(C) The weight of liver and visceral adipose tissues from the perirenal fat pad and subcutaneous fat (SC) from 6-month-old WT and KO mice in absolute weight.
Eight pairs of mice from three independent cohorts of mice fed a normal diet were analyzed.
(D) Food intake by 3-month-old WT and KO mice monitored over 5 days using the metabolic chamber (n = 6). Data are representative of two independent
experiments.
(E) Oxygen consumption as a measure of energy expenditure by 3-month-old WT and KO mice; shown are the average readings from six mice monitored
over 24 hr.
(F) Basal metabolic rate taken as an average of the oxygen consumption rates measured from 7 a.m. to 5 p.m. (n = 6).
(G) Respiratory exchange rate (RER) of 3-month-old WT and KO mice monitored over 5 days (n = 6).
(H) Total horizontal (X) activity of 3-month-old WT and KO mice monitored over 5 days (n = 6).
(I) Total vertical (Z) activity of 3-month-old WT and KO mice monitored over 5 days (n = 6).
(J) Body weight of WT and KO mice were monitored weekly beginning at 2 months of age for 4 months. Data are representative of three independent cohorts of
HFD-fed mice (n = 10).
(K) MRI of WT and KO mice before (2 months old) and 10 or 16 weeks after HFD (n = 10).
*p < 0.05, **p < 0.01. See also Figures S2 and S3.
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Figure 3. Glucose Intolerance, Impaired Insulin Sensitivity, and Insulin Signaling in NUCKS KO Mice
(A) Glucose tolerance tests performed on 3-month-old WT and KO mice fed a normal diet (n = 7).
(B) Area under curve (AUC) was calculated based on the GTT data and is shown on the right panel.
(C) Insulin tolerance tests performed on 3-month-old WT and KOmice fed a normal diet (n = 7). Glucose levels in ITT tests were expressed as fold change relative
to time 0 before insulin injection.
(D) Area above the curve (AAC) was calculated based on the ITT data.
(E–G) Hyperinsulinemic euglycemic clamping of 10-week-old NUCKS WT mice (n = 5) and NUCKS KO mice (n = 4). Glucose infusion rate (GIR) was expressed
as mg/kg.min (E). Percent suppression of hepatic glucose production by insulin was expressed as percentage (F). Glucose disappearance rate was expressed
as mg/kg.min (G).
(H–K) GTT (H–I) and (J and K) ITT of WT and KO mice fed a HFD for 4 months (n = 7). AUC and AAC are shown on the right of these panels, respectively.
(L) Phosphorylation of Akt in liver were checked before and 15min after insulin stimulation (1 U/kg) in 3-month-old NUCKSWT and KOmice. Each lane represents
extracts obtained from individual mouse, and data are representative of three independent cohorts of mice (n = 4 for each experiment).
(legend continued on next page)
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livers (Figures S2K and S2L). No significant differences were
observed in liver triglyceride (TG), high-density lipoprotein
cholesterol, or low-density lipoprotein/very low-density lipopro-
tein cholesterol levels betweenWT and KOmice on an HFD (Fig-
ures S3A and S3B) and in serum triglyceride (TG) or free fatty
acid (FFA) levels between the normal NCD-fed KO and WT
mice (Figures S3C and S3D). Serum leptin and adiponectin levels
were comparable between WT and KO mice fed with the NCD
(Figures S3E and S3F). Consistent with the obese phenotype,
leptin levels were elevated while those of adiponectin were
decreased in HFD-fed NUCKS KO mice (Figure S3G and S3H).
Together, these results, especially the finding that nutrient over-
load exacerbates the metabolic phenotypes in the absence of
NUCKS, suggest that NUCKS plays a role in metabolic homeo-
stasis in vivo.
Impaired Glucose Tolerance and Reduced Insulin
Sensitivity in NUCKS KO Mice
To test whether NUCKS is directly involved in the regulation of
glucose metabolism and insulin signaling at the organism level,
we first measured resting and fasting glucose and insulin levels
of NCD-fed NUCK KO and WT mice. There was no difference
in resting or fasting glucose levels between the two groups,
but resting insulin levels were higher in NUCKS KO mice
compared withWTmice (Figures S4A and S4B; data not shown).
Glucose tolerance tests (GTT) showed that NCD-fed NUCKS KO
mice had higher blood glucose levels at the 30 and 60 min time
points and significantly worse maintenance of glucose levels
during the 120min testing period (Figures 3A and 3B). Consistent
with reduced insulin sensitivity, the KO mice exhibited slower
reduction of glucose levels after insulin injection in insulin toler-
ance tests (ITT) (Figures 3C and 3D). To confirm the insulin-resis-
tance phenotype and the role of NUCKS in regulating glucose
homeostasis, we performed hyperinsulinemic euglycemic clamp
experiments. NUCKSmice exhibited a reduced glucose infusion
rate (Figure 3E), enhanced hepatic glucose production (Fig-
ure 3F), and impaired glucose uptake (Figure 3G). Resting blood
glucose levels in HFD-fed NUCKS KO mice were significantly
elevated compared with HFD-fedWTmice (Figure S4C). Resting
plasma insulin levels were significantly elevated in both HFD-fed
NUCKS KO and WT mice, with NUCKS KO mice showing more
than twice the levels of plasma insulin than the WT mice (Fig-
ure S4D). Similar to the body-weight phenotype, glucose intoler-
ance and insulin resistance were also markedly exacerbated in
HFD-fed NUCKS KO mice when compared with HFD-fed WT
mice (Figures 3H–3K). To investigate the molecular basis under-
lying the observed metabolic phenotype, including reduced
insulin sensitivity in vivo, we next examined insulin signaling in
tissues of WT and KO mice. Consistent with decreased insulin
signaling observed in cell lines (Figures S1J–S1N), insulin-stimu-
lated phosphorylation of Akt was significantly attenuated in livers
andWATof NUCKSKOmicewhen comparedwithWTmice (Fig-(M) Quantification of P-Akt normalized to total Akt is shown on the right (n = 4).
(N) Strength of insulin signaling in WAT as judged by Akt phosphorylation after 15
(O) Quantification of P-Akt normalized to total Akt is shown on the right (n = 4). D
(P and Q) Akt phosphorylation before and 15 min after insulin stimulation in liver,
*p < 0.05, **p < 0.01. See also Figure S4.
Cures 3L–3O). Similarly, insulin-dependent Akt phosphorylation
was also suppressed in the WAT and livers of NUCKS KO mice
on an HFD (Figures 3P and 3Q). Consistent with lower p-Akt acti-
vation in NUCKS KO livers, we observed higher levels of mRNAs
encoding gluconeogenic enzymes fructose 1, 6 bisphosphatase
1 (Fbp1) and glucose-6-phosphatase (G6P) in the KO livers (Fig-
ure S4E) and higher glucose output in the KO mouse primary
hepatocytes (Figure S4F). Taken together, these results support
the notion that NUCKS is a positive regulator of glucose meta-
bolism and insulin signaling in vivo.
Genome-wide Approach Identifies NUCKS as a Key
Integrator of Metabolic Signaling
It is clear from our assays that NUCKS has an important role in
regulating glucose homeostasis and loss of NUCKS leads to
obesity. Toget anunbiasedhandle on theplausiblemechanism(s)
of NUCKS action, we performed a genome-wide ChIP-seq for
NUCKS in primary hepatocytes. We successfully mapped
25 mln reads to the mm9 genome and detected NUCKS binding
at 10,203 sites, 60% of which were located in the proximity of a
transcription start site (TSS) (Figure 4A). The peaks of NUCKS
occupancy were often broad, with some around 1 kb (Figure 4B),
suggesting that multiple NUCKS molecules could bind coopera-
tively to the same genomic loci. Gene Ontology and signaling
pathway analyses of NUCKS-bound genes revealed that 16 of
the top 20 pathways were metabolic and biosynthetic processes
and that the insulin signaling pathway was represented with high
significance in the top categories, with cytokine secretion/
signaling being the other most prominent module (Figures 4C
and 4D). We also performed de novo motif discovery to identify
specific sequences bound by NUCKS (Figure 4E). Interestingly,
we identified motifs resembling those bound by SP1, which has
been previously shown to be involved in the regulation of the IR
(Brunetti et al., 2001; Foti et al., 2003, 2005). Since ChIP
sequencing revealed that NUCKS bound the TSS of a few mem-
bers of the insulin signaling pathway (Table S3), we validated
theChIP data and also checkedwhether NUCKSbinding to these
genes regulates their expression. Indeed, NUCKS could bind the
promoter regions of a few genes in the insulin pathway, including
IRb, IRS1, IRS2, and PDK1 (Figure 4F). These results suggest
that NUCKS-mediated regulation of key insulin signaling genes
like IR and some other targets like PDK1, Rictor, andDeptor con-
tributes to the metabolic phenotype of the NUCKS KO mice.
NUCKS Regulates IR Transcription by Opening
Chromatin and Enhancing Pol II Recruitment
We next examined the molecular mechanism of NUCKS-medi-
ated transcription, especially that of IRb. We generated lucif-
erase reporter constructs driven by the first 2,000 bp of the
mouse or human IR promoter region. Overexpression of NUCKS
led to increased IR transcription, whereas NUCKS-DC, a C-ter-
minal deletion mutant lacking the DBD (Figure S1I), failed tomin of insulin stimulation (1 U/kg). Each lane represents an individual mouse.
ata are representative of two independent cohorts of mice.
and WAT obtained from mice fed an HFD for 4 months.
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induce the IR promoter (Figure 5A), suggesting direct binding of
NUCKS to the IR promoter/enhancer is essential for IR transcrip-
tion. According to a previous report, HMGA1, one of the high-
mobility group family members, binds to a specific probe from
the IR promoter and regulates IR transcription (Foti et al.,
2003). An electrophoretic mobility shift assay found that NUCKS
could directly bind to the human and mouse IR probes (Fig-
ure 5B). The specificity of the interaction was confirmed using
cold competition (Figure 5B, lane 3). To gain further mechanistic
insights, we checked if NUCKS regulates openness of chromatin
and Polymerase II (Pol II) recruitment to the IR promoter. Using
the formaldehyde-assisted isolation of regulatory elements
(FAIRE) method (Simon et al., 2012), which assesses the level
of open chromatin, we found that depletion of NUCKS in primary
hepatocytes decreased the degree of open chromatin in the IR
promoter at the TSS (Figure 5C). Concomitantly, loss of NUCKS
led to reduce Pol II recruitment at the TSS (Figure 5D). We
checked IR mRNA levels in primary hepatocytes from WT and
KO mice fed an NCD and HFD and loss of NUCKS leads to a
reduction of IRmRNA (Figure 5E). Wemade use of in vitro mouse
embryonic fibroblast (MEF)-differentiated adipocyte culture
derived from WT and KO mice. Akt phosphorylation was signifi-
cantly attenuated in NUCKS KO MEF-differentiated adipocytes
(Figures 5F and 5G).Moreover, we found that IRbprotein expres-
sion was dramatically reduced in the KO MEF adipocytes when
compared with WT cells (Figures 5F and 5G), along with a corre-
sponding reduction in IRb transcript levels (Figure 5H). Consis-
tent with the findings in primary cells (Figures 5E–5H), we also
observed dramatic changes of IR in adipose and liver tissue
from HFD-fed mice (Figures 5I–5K). As the ChIP-sequencing re-
sults showed that NUCKS also binds to members of the insulin
signaling pathway, we checked the mRNA and protein levels of
those members between WT and KO mouse hepatocytes and
found that NUCKS also regulates the expression of Deptor and
PDK1 (Figures S5A and S5B), suggesting that NUCKS might
target a few key players in the insulin signaling pathway (Fig-
ure 5L). Further study will delineate how NUCKS regulates these
genes in a context- and cell-type-specific manner. Taken
together, these results define the molecular mechanism of
NUCKS action and explain how it transcriptionally regulates IR
and other members of the insulin signaling pathway and hence
impacts insulin signaling.
DISCUSSION
Numerous studies have focused on the transcriptional, transla-
tional, and posttranslational modifications of insulin, insulinFigure 4. Genome-wide ChIP Sequencing of NUCKS
(A) Genome-wide distribution of NUCKS-bound sites. Approximately 60% of pea
(B) Density of NUCKS binding across all RefSeq annotated TSSs.
(C) NUCKS-bound promoter regions of genes enriched very significantly for met
(D) Gene Ontology analysis of pathways from NUCKS ChIP-seq results. These pe
significance), including the insulin pathway (false discovery rate q-value = 6.2761
(E) NUCKS-bound sites were enriched for motifs associated with SP1 (e-value =
(F) Quantification of DNA enrichment after immunoprecipitation with NUCKS-spe
quantitative PCR and normalized to DNA input. Chromatin enrichment of each m
elsewhere in the chromosome.
All data shown are representative of three independent experiments.
Csecretion, and insulin-driven signal transduction (Emanuelli
et al., 2000; Gonza´lez-Rodrı´guez et al., 2010; Taniguchi et al.,
2006). However, mechanisms that respond to dietary cues
and/or contribute to direct transcriptional regulation of insulin
signaling components are poorly elucidated. In this study, by
using unbiased proteomic and genomic approaches, we report
the identification and characterization of NUCKS as a transcrip-
tional regulator of metabolic processes and insulin signaling.
This study demonstrates that NUCKS regulates energy and
glucose homeostasis. NUCKS expression inversely correlates
with obesity in both humans and mice, and it is sensitive to star-
vation or HFD. Mice deficient in NUCKS in all the tissues are
obese, with increased body fat content, and display decreased
locomotor activities, hyperphagia, and reduced energy expendi-
ture. Whole-body deletion of NUCKS also leads to glucose
intolerance and impaired insulin sensitivity, accompanied by
elevated serum insulin levels. We further show that NUCKS reg-
ulates transcription of members of the insulin signaling pathway,
including IR (by binding to IR promoter/enhancer sequences),
and regulates its chromatin context to allow Pol II recruitment
at the TSS. Much like NUCKS, it is well documented that IR
expression levels correlate with starvation and nutritional status
both in tissue culture cells and in animals (Hatada et al., 1989;
Puig and Tjian, 2005). The genome-wide ChIP-seq approach
also showed with very high confidence (false discovery rate
q-value = 6.27616 3 1031) that insulin signaling is among the
top signaling pathways regulated by NUCKS. This unbiased
approach not only ratified our observations that the insulin pro-
moter is bound and regulated by NUCKS but also identified a
few key players in insulin signaling that could be both bound
and regulated by NUCKS. These findings could explain how
NUCKS positively regulates AKT downstream of insulin in an
IR-dependent and IR-independent manner and may suggest a
more physiological manner in which these processes are regu-
lated in nature.
Although complete loss of IR leads to early lethality in mice,
loss of IR in different tissues or within regions of a given tissue
has very distinct phenotypes (Kitamura et al., 2003). While it is
tempting to speculate that NUCKS-mediated effects are largely
due to loss of IR, it is also important to discern that NUCKS loss is
not synonymous with IR loss. NUCKS deletion leads only to par-
tial loss of IR, and other HMGAproteinsmay compensate for loss
of NUCKS in some tissues or cells. In addition, NUCKS has other
targets that regulate insulin signaling (Figure 5L), and it is not un-
common for transcription factors like nuclear factor kB or Myc to
regulate multiple members of a signaling cascade to regulate the
physiological effect (Ang and Tergaonkar, 2007; Cildir et al.,ks are within 5 kb of a known transcription start site (TSS).
abolic processes.
aks are also highly enriched for genes involved in several pathways (with similar
6 3 1031).
8.3 3 1066) and STAT1/3 (e-value = 4.6 3 1058).
cific antibody from mouse primary hepatocytes. ChIP DNA was quantified by
otif has been documented as fold change over enrichment of a control region
ell Reports 7, 1876–1886, June 26, 2014 ª2014 The Authors 1883
A B
C D E
F G H
I
J
K
L
(legend on next page)
1884 Cell Reports 7, 1876–1886, June 26, 2014 ª2014 The Authors
2013; Dang, 2012; Tergaonkar, 2006). Since loss of NUCKS is
also seen in individuals with a high BMI, and since NUCKS levels
could be modulated by diet, this offers the exciting possibility
that NUCKS could be a worthwhile molecular target for thera-
peutic intervention. Given the number of signaling cascades
that covalently modify NUCKS (Wisniewski et al., 2008), it is
highly likely that modifications of NUCKS could link insulin
signaling and energy homeostasis to changes in myriad cellular
processes regulated by these enzymes.
In summary, we have identified NUCKS as a positive regulator
of members of the insulin signaling pathway, including IR
transcription, that could play a role in regulating insulin signaling.
Future studies directed at understanding its tissue- and stimuli-
specific downstream targets may provide promising therapeutic
approaches in the treatment of obesity and insulin resistance.
We also hypothesize that unlike studying the function of mice
with complete depletion of single-candidate targets like IR,
which are not reflective of human physiology, molecules like
NUCKS, which are central regulators of a few key molecules
and levels of which respond clinically in response to diet, provide
a better understanding of physiology. Given that signaling com-
ponents are shared amongmany pathways, the subtle regulation
of multiple inputs rather that ‘‘on-off’’ regulation of a key member
ensures easy return to homeostasis. Hence, nature uses rheo-
stats like NUCKS that fine-tune response via signaling through
additive inputs.
EXPERIMENTAL PROCEDURES
Animal Welfare
All animals were kept on a 12 hr light-dark cycle. All procedures involving
animal experimentation were approved by the Institutional Animal Care and
Use Committee of A*STAR.
Chromatin Immunoprecipitation Assays, Formaldehyde-Assisted
Isolation of Regulatory Elements Analysis, and ChIP-Seq Library
Preparation
Cells were crosslinked with 1% paraformaldehyde for 20 min at room temper-
ature. The reaction was quenched for 10 min at room temperature by addingFigure 5. NUCKS Positively Regulates Insulin Receptor Transcription
(A) 293T cells were transfected with the indicated plasmids and harvested for a d
used for luciferase activity measurement, and firefly luciferase activity was normal
insulin receptor (hInsR-luc) and mouse insulin receptor (mInsR-luc) promoter fu
eliminates this effect. Levels of NUCKS proteins are shown in the panel below.
(B) Electrophoretic mobility shift assay with NUCKS binding site probes with lysat
(the sequences are shown below the figure).
(C) Open chromatin (% of input) in the mouse IR promoter region in WT and KO
(D) Fold enrichment of Pol II binding to the mouse IR TSS region in WT and KO m
(E) IR mRNA levels in WT and KO mouse primary hepatocytes with the NCD and
(F) WT and KOMEFs were differentiated into adipocytes and harvested on day 8 a
an independent clone of an MEF.
(G) Quantification normalized levels of IR, p-Akt(S473), and pAkt(T308) in (F).
(H) Transcript level of IR in day 8 adipocyte culture quantified by quantitative RT
representative of two or three independent experiments.
(I and J) Western analysis of liver and WAT extracts obtained from mice on an HF
(liver, n = 16; adipose, n = 11).
(K) Quantitative RT-PCR analysis of IR transcript in WAT (n = 9). Expression leve
(L) Scheme of NUCKS’s mechanism to regulate insulin signaling. Black arrows st
phosphorylation by upstream kinase.
*p < 0.05, **p < 0.01. See also Figure S5.
C0.125 M glycine and the washed cell pellet frozen at 80C. Cell pellets
were lysed and centrifuged at 12,0003 g for 1 min at 4C. Sheared chromatin
generated from cell pellets by sonication was incubated with NUCKS antibody
or control rabbit immunoglobulin G overnight at 4C. The immunocomplexes
were precipitated with 20 ml preblocked protein A-agarose beads (1 hr at
4C) and washed extensively. Reversion of crosslinking was performed over-
night by heating samples and input at 65C, and DNA was purified using the
QIAquick spin kit (QIAGEN). Open chromatin was prepared by the FAIRE
method (Simon et al., 2012) and followed by quantitative PCR analysis.
Libraries were prepared using a standard Illumina pipeline and sequenced
using a 50 bp single-end format on an Illumina HiSeq 2000 as previously
described with minor variations (Migliori et al., 2012). The Sample Prep oligo-
nucleotide kit (Illumina) was used for barcoding/multiplexing.
Statistics
Statistical analysis between two groups was performed by Student’s t test
using PRISM software. Statistical significance of ITT and GTT curves was
determined by comparing differences in area above the curve or under the
curve. Data are presented as mean ± SEM (*p < 0.05, **p < 0.01, ***p <
0.001). For further details, please refer to Supplemental Experimental
Procedures.
ACCESSION NUMBERS
The GEO accession number for the genome-wide ChIP sequencing of NUCKS
data reported in this paper is GSE58100.
SUPPLEMENTAL INFORMATION
Supplemental Information contains Supplemental Experimental Procedures,
five figures, and three tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2014.05.030.
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ized to Renilla luciferase activity. NUCKS increases transcription of both human
sions with luciferase gene as a reporter, while C-terminal deletion of NUCKS
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